Janus Living, Inc.
No SEC Form 4 filings for $JAN in the last 30 days.
Janus Living (NYSE:JAN) reported sequential same-store NOI margin down 40 bps, citing seasonality. Occupancy rose for independent living but fell for skilled nursing. The company acquired two communities for $105M, sold one for $23M, and completed $1B more acquisitions post-quarter. It raised 2026 FFO guidance to $0.95-$0.98 and same-store adjusted NOI growth to 13%-17%.
Janus Living, Inc. (JAN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.3 4 ex99306302026.htm EX-99.3 Document Exhibit 99.3 Discussion and Reconciliation of Janus Living's Non-GAAP Financial Measures June 30, 2026 (Unaudited) Definitions Adjusted Fixed Charge Coverage Fixed Charge Coverage Adjusted EBITDAre divided by Fixed Charges. Adjusted Fi
Healthcare rose more than 6% in June as investors favored defensives over tech. Raymond James refreshed its healthcare top-picks list, adding UnitedHealth Group (UNH) and Janus Living (JAN). UNH is up 28% YTD; Q1 adjusted EPS $7.23 on $111.72B revenue; raised dividend to $2.32. JAN, an REIT, debuted in March IPO at $20 and closed at $28.99; dividend yield 1.96%.
Over the past 7 days, alphai's AI scored 2 news stories mentioning JAN (Janus Living, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent JAN coverage spans market movers, earnings and sector analysis.
Guidance raises and occupancy/NOI commentary suggest improving fundamentals, supported by large acquisition deployment and strong liquidity.
This filing is primarily metric-definition boilerplate, not a new earnings datapoint or guidance change.
The stock gets a fresh buy-list endorsement tied to occupancy/margin recovery and deal-sourcing tailwinds, which can influence flows.
New coverage with a defined PT supports a bullish re-rating narrative for the senior living REIT.
Street targets moved higher for JAN, reinforcing a bullish near-term sentiment backdrop after the latest earnings/guidance context.
alphai scores every news story that mentions JAN with an AI model for sentiment and relevance, and aggregates insider trades from Janus Living, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Janus Living (NYSE:JAN) reported sequential same-store NOI margin down 40 bps, citing seasonality. Occupancy rose for independent living but fell for skilled nursing. The company acquired two communities for $105M, sold one for $23M, and completed $1B more acquisitions post-quarter. It raised 2026 FFO guidance to $0.95-$0.98 and same-store adjusted NOI growth to 13%-17%.
6 min readJanus Living, Inc. (JAN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.3 4 ex99306302026.htm EX-99.3 Document Exhibit 99.3 Discussion and Reconciliation of Janus Living's Non-GAAP Financial Measures June 30, 2026 (Unaudited) Definitions Adjusted Fixed Charge Coverage Fixed Charge Coverage Adjusted EBITDAre divided by Fixed Charges. Adjusted Fi
2 min readHealthcare rose more than 6% in June as investors favored defensives over tech. Raymond James refreshed its healthcare top-picks list, adding UnitedHealth Group (UNH) and Janus Living (JAN). UNH is up 28% YTD; Q1 adjusted EPS $7.23 on $111.72B revenue; raised dividend to $2.32. JAN, an REIT, debuted in March IPO at $20 and closed at $28.99; dividend yield 1.96%.
6 min readWall Street analysts issued a range of calls on Wednesday. Bernstein initiated GE Vernova (outperform), NeoVolta (buy, $8 PT) and reiterated Nvidia (outperform). Deutsche Bank raised Micron’s PT to $1,500 ahead of next week’s earnings. Bernstein also lifted AMD to $600, Intel to $100, and Arm to $500. Morgan Stanley downgraded ResMed to equal weight; Citi initiated Figma (buy, $36 PT).
3 min readBenzinga reports Wells Fargo raised its JAN (NYSE:JAN) target price to $31 from $27 and kept an “overweight” rating, implying 20.89% upside. Other firms also issued bullish targets (e.g., Barclays $30, BofA $29). JAN traded at $25.64 on Monday. The company reported $0.23 EPS and $200.35M revenue in its May 5 quarter.
3 min readAnalysts at several firms adjusted ratings and price targets for JAN (NYSE: JAN) in May 2026, with Scotiabank raising its target to $30 (from $28) and Barclays lifting to $30 (from $26), among others. In April, multiple firms initiated coverage with targets from $26 to $29. JAN also declared a quarterly dividend of $0.1599 per share, payable June 24 to holders of record June 12.
4 min read
